Oncolytics Biotech Inc
TSX:ONC
Oncolytics Biotech Inc
Net Income (Common)
Oncolytics Biotech Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Oncolytics Biotech Inc
TSX:ONC
|
Net Income (Common)
-CA$27.8m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-2%
|
|
Zymeworks Inc
NYSE:ZYME
|
Net Income (Common)
-$118.7m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Net Income (Common)
-$93.8m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Net Income (Common)
-$94.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Net Income (Common)
-$62.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-25%
|
|
Spectral Medical Inc
TSX:EDT
|
Net Income (Common)
-CA$15.7m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-3%
|
See Also
What is Oncolytics Biotech Inc's Net Income (Common)?
Net Income (Common)
-27.8m
CAD
Based on the financial report for Dec 31, 2023, Oncolytics Biotech Inc's Net Income (Common) amounts to -27.8m CAD.
What is Oncolytics Biotech Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-2%
Over the last year, the Net Income (Common) growth was -12%. The average annual Net Income (Common) growth rates for Oncolytics Biotech Inc have been -7% over the past three years , -10% over the past five years , and -2% over the past ten years .